CoChat

Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial

Wang, Kang, Xiang, Yan-Jun, Yu, Hong-Ming, Cheng, Yu-Qiang, Liu, Zong-Han, Qin, Ying-Yi, Shi, Jie, Guo, Wei-Xing, Lu, Chong-De, Zheng, Ya-Xin, Zhou, Fei-Guo, Yan, Mao-Lin, Zhou, Hong-Kun, Liang, Chao, Zhang, Fan, Wei, Wen-Jing, Lau, Wan Yee, Li, Jing-Jing, Liu, Yan-Fang, Cheng, Shu-Qun · 2024 · Nature Medicine

The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.

Abstract

Hepatocellular carcinoma (HCC), particularly when accompanied by microvascular invasion (MVI), has a markedly high risk of recurrence after liver resection. Adjuvant immunotherapy is considered a promising avenue. This multicenter, open-label, randomized, controlled, phase 2 trial was conducted at six hospitals in China to assess the efficacy and safety of adjuvant sintilimab, a programmed cell death protein 1 inhibitor, in these patients. Eligible patients with HCC with MVI were randomized (1:1) into the sintilimab or active surveillance group. The sintilimab group received intravenous injections every 3 weeks for a total of eight cycles. The primary endpoint was recurrence-free survival (RFS) in the intention-to-treat population. Key secondary endpoints included overall survival (OS) and safety. From September 1, 2020, to April 23, 2022, a total of 198 eligible patients were randomly allocated to receive adjuvant sintilimab (n = 99) or undergo active surveillance (n = 99). After a median follow-up of 23.3 months, the trial met the prespecified endpoints. Sintilimab significantly prolonged RFS compared to active surveillance (median RFS, 27.7 versus 15.5 months; hazard ratio 0.534, 95% confidence interval 0.360-0.792; P = 0.002). Further follow-up is needed to confirm the difference in OS. In the sintilimab group, 12.4% of patients experienced grade 3 or 4 treatment-related adverse events, the most common of which were elevated alanine aminotransferase levels (5.2%) and anem…

Overview

Integrity signals

Registry

Crossref · 10.1038/s41591-023-02786-7

Cites

55 of 55 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 55 references

Cited by

See all 157

Metadata

Authors
Wang, K., Xiang, Y.-J., Yu, H.-M., Cheng, Y.-Q., Liu, Z.-H., Qin, Y.-Y., Shi, J., Guo, W.-X., Lu, C.-D., Zheng, Y.-X., Zhou, F.-G., Yan, M.-L., Zhou, H.-K., Liang, C., Zhang, F., Wei, W.-J., Lau, W. Y., Li, J.-J., Liu, Y.-F., & Cheng, S.-Q.
Affiliations
  • Second Military Medical University (CN)
  • Eastern Hepatobiliary Surgery Hospital (CN)
  • Fujian Provincial Hospital (CN)
  • Shanghai University of Traditional Chinese Medicine (CN)
  • Binzhou Medical University (CN)
  • Chinese University of Hong Kong (HK)
  • Shanghai Institute of Nutrition and Health (CN)
Venue
Nature Medicine
Published
2024-01-19
Volume
30
Issue
3
Pages
708-715
ISSN
  • 1078-8956 (ISSN-L)
  • 1546-170X
OpenAlex
W4391027452
Cited by
142
References
54
Citations by year
2026: 44 · 2025: 59 · 2024: 39
FWCI
37.17
Type
journal article
Language
en
Open access
closed
Licence
Locations
  • Nature Medicine (publishedVersion)
  • PubMed (publishedVersion)
Funders
National Natural Science Foundation of China (82072618)
Topics
  • Health Sciences › Medicine › Hepatology › Hepatocellular Carcinoma Treatment and Prognosis
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Health Sciences › Medicine › Epidemiology › Hepatitis B Virus Studies
Keywords
hepatocellular carcinoma, sintilimab, adjuvant immunotherapy, microvascular invasion, hepatectomy, recurrence-free survival, PD-1 inhibitors, immune checkpoint inhibitors, active surveillance, overall survival, treatment-related adverse events
MeSH terms
Adjuvants, Immunologic, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Hepatocellular, Humans, Liver Neoplasms, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial. https://app.cochat.ai/papers/10.1038/s41591-023-02786-7
The paper
Wang, K., Xiang, Y.-J., Yu, H.-M., Cheng, Y.-Q., Liu, Z.-H., Qin, Y.-Y., Shi, J., Guo, W.-X., Lu, C.-D., Zheng, Y.-X., Zhou, F.-G., Yan, M.-L., Zhou, H.-K., Liang, C., Zhang, F., Wei, W.-J., Lau, W. Y., Li, J.-J., Liu, Y.-F., & Cheng, S.-Q. (2024). Adjuvant sintilimab in resected high-risk hepatocellular carcinoma: a randomized, controlled, phase 2 trial. Nature Medicine. https://doi.org/10.1038/s41591-023-02786-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.